Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 86

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 86
---
5.25 years and an option to extend for an additional
three years, with a monthly rent of $7,206 per month, subject to increase at the rate of 3% per year. All of such space is leased from
a non-affiliated third party.

We
believe that the above facilities are adequate for our current needs and have sufficient laboratory space to house additional scientists
as we grow.

Item
3. Legal Proceedings

Currently,
there are no legal proceedings pending or threatened against us. We are not presently party to any pending or other threatened legal
proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results,
although from time to time, we may become involved in legal proceedings in the ordinary course of business.

Item
4. Mine Safety Disclosures

Not
applicable.

54

PART
II

Item
5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market
Information

Our
common stock commenced trading on the Nasdaq Capital Market, under the symbol “SHPH” on August 31, 2022. Prior to that time,
our common stock was not traded on any exchange or quoted on any over the counter market.

Holders

As
of February 7, 2025, we had 61 holders of record of our common stock and 4,076,567 shares of common stock issued and outstanding.

Dividends

We
have not paid any dividends on our common stock since inception and we currently expect that, in the foreseeable future, all earnings
(if any) will be retained for the development of our business and no dividends will be declared or paid on our common stock. Any future
dividends on our common stock will be subject to the discretion of our board of directors and will depend upon, among other things, our
earnings (if any), operating results, financial condition and capital requirements, general business conditions and other pertinent facts.

Preferred
dividends

As
of the date of this Annual Report, we have not issued any preferred stock nor paid any preferred dividends.

Recent
Sales of Unregistered Securities

During
the past three years, we effected the following transactions in reliance upon exemptions from registration under the Securities Act:

On
February 8, 2022 and March 11, 2022, the Company sold to certain accredited investors $365,000 and $225,000, respectively, in